


# The RIFM sensitization research projects have focused on New Approach Methodologies (NAMs)






# RIFM ensures the safe use of fragrance materials through our safety assessment program.

Step 1: Data


Step 2: Read-Across

Step 3: Threshold for Toxicological Concern (TTC)

Step 4: Testing OR Risk Management



ifra





standards

The IFRA Standards form the basis for the globally accepted and recognized risk management system for the safe use of fragrance ingredients and are part of the IFRA Code of Practice.

This is the self-regulating system of the industry, based on risk assessments carried out by an independent Expert Panel.

# Our staff works on two complimentary scientific endeavors to bring the best science to fragrance material safety

## Endpoint Assessments



## Research

Exposure Methodologies

Improved/Alternative Test Methodologies

*In Silico* Models

# The RIFM sensitization research projects have focused on NAMs to identify sensitization potency

## Human Data



- Human potency categorization (Api,2017)
- Publication of all RIFM conducted HRIPTs (in progress)

## Human + LLNA Data



- Correlation of human and LLNA induction thresholds (Api,2014; in progress)

## Animal Data



- Contribute to the development of **Lhasa's** EC3 and Negative Prediction Models (Canipa,2017 & Chilton,2018)

## *In Chemico/In Vitro* Data




- **EDELWEISS CONNECT**
- Recategorization of human categories utilizing additional data

## DST



- Integration of high potency chemicals (Roberts,2015) into **OASIS TIMESS 2.28.1**
- Working w/ Bob Safford to strengthen the DST dataset
- Working w/ **Lhasa** and Frank Gerberick to predict NESILs using EC3 predictions and DST


**The main focus of the RIFM skin sensitization research is developing alternatives to animal testing and determining potency**



# **Dermal Sensitization Threshold (DST) identifies an exposure below which there is no appreciable risk for the induction of skin sensitization for an untested chemical**

- RIFM collaborated with R Safford and D Roberts to extend DST for reactive chemicals and identify high potency chemicals
  - Safford, R.J., Api, A.M., Roberts, D.W., Lalko, J.F., 2015. Extension of the Dermal Sensitisation Threshold (DST) approach to incorporate chemicals classified as reactive. *Regulatory Toxicology and Pharmacology*, 72, 694-701.
  - Roberts, D.W., Api, A.M., Safford, R.J., Lalko, J.F., 2015. Principles for identification of High Potency Category Chemicals for which the Dermal Sensitisation Threshold (DST) approach should not be applied. *Regulatory Toxicology and Pharmacology*, 72, 683-693
- RIFM currently collaborating with scientists at Kao to develop a DST for high potency chemicals

# RIFM is leading the effort in combining multiple in vitro methods to predict skin sensitization potency





# Reliable animal and human data are required for appropriate in vitro data evaluation and predictive models

Api,  
2014

Correlation of human and LLNA induction thresholds

In  
Progress

Correlation of human and LLNA induction thresholds  
**Part II**

Api,  
2017

Skin sensitization potency categorization based on human data

In  
Progress

Compilation of RIFM conducted HRIPTs

In  
Progress

Pilot study on the new HRIPT protocol

In  
Progress

Skin sensitization potency **re-categorization**

In  
Progress

Comparison of re-categorized skin sensitization potency and SENS-IS data



# Skin sensitization potency re-categorization incorporates more than just human data

## Re-Categorization

**1**

Test material id

- discrete chemical or mixture?
- stabilizer information

**2**

Human data

- LOELs where available
- the highest NESIL
- other HRIPT, hMAX LOEL

**3**

LLNA data

- EC<sub>3</sub>

**4**

Chemistry Predictions

- OECD Toolbox
- OASIS TIMESS

**5**

In vitro data

- DPRA, PPRA
- KeratinoSens, h-CLAT
- SENS-IS

**6**

Other in vivo data

- guinea pig studies

**7**

Exposure data

- Creme-RIFM aggregate exposure model

**8**

Diagnostic patch test

# Ranges were modified for the re-categorization

<b>Category Name</b>	<b>LLNA (<math>\mu\text{g}/\text{cm}^2</math>)</b>	<b>Basketter (<math>\mu\text{g}/\text{cm}^2</math>)</b>	<b>Modified Basketter (<math>\mu\text{g}/\text{cm}^2</math>)</b>
<b>Extreme</b>	<25	<25	<25
<b>Strong</b>	25 - 250	25 - 500	25 - 500
<b>Moderate</b>	250 - 2,500	500 - 2,500	500 - 2,500
<b>Weak</b>	2,500 - 25,000	2,500 - 10,000	2,500 - 5,000
<b>Very Weak</b>	---	> 10,000	>5,000
<b>Non Sensitizer</b>	---	Negative	---


# We went through this exercise for 75 materials and categories for 22 materials were changed

			HRIPT				HRIPT	HRIPT	LLNA	DPRA	PPRA	Keratinosens	h-CLAT	SENS IS	ToolBox	TIMESS	TIMESS
	CAS Number	Chemical Name	Category Range (Api, 2017)	Category Name (modified Api,2017)	Category Range (µg/cm <sup>2</sup> ) (modified Api,2017)	Human Categorization Notes (2017 vs 2019 difference)	NESIL (µg/cm <sup>2</sup> )	LOEL (µg/cm <sup>2</sup> )	LLNA	DPRA	PPRA	Keratinosens	h-CLAT	SENS-IS	Protein binding alerts for skin sensitization by OASIS	Parent Prediction	Metabolite Prediction
1	6728-26-3	Hexen-2-al	25 - 500				24	236	1012 [2]	Strong	HR			Strong	Michael Addition	Strong sensitiser	Non sensitiser
2	3658-77-3	4-Hydroxy-2,5-dimethyl-3(2H)-furanone	500 - 2,500				590	1181	450	Strong	HR			Weak	No alert found	Non sensitiser	Weak sensitiser
3	122-03-2	Cuminic Aldehyde	2,500 - 10,000			Rate - *NESIL no effect level not THE no effect level (LLNA (SI = 2.0 @ 10%) and HMAX (2760))	1100*	n/a	>2500	Low				Moderate	Schiff Base	Weak sensitiser	Weak sensitiser
4	68991-97-9	1,2,3,4,5,6,7,8-Octahydro-8,8-dimethyl-2-naphthaldehyde	500 - 2,500	Moderate	500 - 2,500		550	n/a	1050	Minimal	MR	Negative	Positive	Non-sensitizer	Schiff Base	Weak sensitiser	Weak sensitiser
5	1885-38-7	Cinnamyl nitrile	500 - 2,500	Moderate	500 - 2,500		1060	1938	>2500	Minimal	MR	Positive	Positive	Moderate	No alert found	Non sensitiser	Strong sensitiser
6	123-11-5	p-Methoxybenzaldehyde	2,500 - 10,000	Weak	2,500 - 5,000		3,500	4,700	>6250	Moderate	R	Negative	Positive	Weak	No alert found	Non sensitiser	Non sensitiser
7	18794-84-8	β-Farnesene	2,500 - 10,000	Weak	2,500 - 5,000	Mixture of isomers; with BHT	3,700	6350	>7500	Minimal	R	Positive	Positive	Non-sensitizer	No alert found	Non sensitiser	Weak sensitiser
8	100-51-6	Benzyl alcohol	2,500 - 10,000	Very weak*	>5,000	Top use categories: Facial scrubs, EDP/EDT	5,900	8,858	>12,500	Minimal	R	Positive/Negative	Positive	Weak	No alert found	Non sensitiser	Non sensitiser
9	54464-57-2	1-(1,2,3,4,5,6,7,8-Octahydro-2,3,8,8-tetramethyl-2-naphthalenyl)ethanone (OTNE)	> 10,000	Very weak	> 5,000	Do we consider NS?	47,000	n/a	3783 [3]	Strong/Low	MR	Negative	Positive	Weak	Nucleophillic Addition	Weak sensitiser	Weak sensitiser

75 materials


22 materials

# Multiple sources of information are used when evaluating a fragrance material




<b>Phys-chem, Reactivity, Absorption &amp; Metabolism, In silico tools</b>	<b>In chemico In vitro studies</b>	<b>Mouse and Guinea pig Studies</b>	<b>Human data</b>
<u>OECD QSAR Toolbox</u>	<u>DPRA</u> (KE 1)	<u>Local Lymph Node Assay</u> (KE 4)	<u>Human Repeated Insult Patch Test (HRIPT)</u> (AO)
TIMES-SS DEREK NEXUS	<u>KeratinoSens</u> <sup>TM</sup> <u>hCLAT</u> (KE 2 + 3)	<u>GP Maximization Test</u> <u>GP Buehler Test</u> (AO)	
Toxtree, SAM	PPRA, kDPRA, U-Sens <sup>TM</sup> , Sens-IS <sup>®</sup>	GP: OET, CET, FCAT, DT	H-Maximization test
		Mouse ear swelling test	Diagnostic Patch tests

# In vitro data in Safety assessment




Phenylacetaldehyde  
(CAS# 122-78-1)



2-Phenylpropionaldehyde  
(CAS# 93-53-8)

	KE-1	KE-2	KE-3	KE-4	Adverse Outcome	
	DPPA % depletion	Keratino Sens™ μM	h-CLAT μg/ml EC150 (CD86) and EC 200 (CD54)	LLNA [# of studies] μg/cm <sup>2</sup>	HRIPT μg/cm <sup>2</sup>	
	C = 60.7% K = 22.63%	EC1.5 = 28.5	EC150 = 17.30; EC 200 = 13.00	962 [2]	LOEL	NOEL
	C = 26.59 K = 5.1	EC1.5 = 111.6	EC150 = 38.20; EC 200 = 44.50	1575 [1]	1181	591
					1938	388


# When the fragrance material cinnamyl acetate was being reviewed the first step in the process was to evaluate all the data on the material






































103-54-8 Cinnamyl acetate

Animal Data	Human Data	In-vitro	In-silico prediction	Clears reactive DST?	details of the reactivity prediction-->	Protein binding alerts for skin sensitization by OASIS Toolbox 4.3.1	Protein binding alerts for skin sensitization by OASIS, with Autoxidation simulator Toolbox 4.3.1	Protein binding alerts for skin sensitization by OASIS, with Skin metabolism simulator Toolbox 4.3.1	Parent Predicted SkinSens (TIMES)	Metabolite Predicted SkinSens (TIMES)	Toxtree 3.1.0
No Data	Neg hMAX @5%	Neg DPRA, Neg h-CLAT	Reactive	No		SN2 >> SN2 Reaction at a sp3 carbon atom >> Activated alkyl esters and thioesters	SN2 >> SN2 Reaction at a sp3 carbon atom >> Activated alkyl esters and thioesters	SN2 >> SN2 Reaction at a sp3 carbon atom >> Activated alkyl esters and thioesters; No alert found; SN2 >> Ring opening SN2 reaction >> Epoxides, Aziridines and Sulfuranes	Weak sensitiser	Strong sensitiser	Acyl Transfer; Michael Acceptor; SN2




































# The next step was to evaluate all the structurally related materials
























 <p>7493-80-3; alpha-Amylcinnamyl isovalerate</p>	 <p>68133-75-5; cis-3-Hexenyl cinnamate</p>	 <p>122-67-8; Isobutyl cinnamate</p>	 <p>122-68-9; 3-Phenylpropyl cinnamate</p>	 <p>103-54-8; Cinnamyl acetate</p>	 <p>103-36-6; Ethyl cinnamate</p>
 <p>103-56-0; Cinnamyl propionate</p>	 <p>7778-83-8; Propyl cinnamate</p>	 <p>7779-65-9; Isoamyl cinnamate</p>	 <p>103-53-7; Phenethyl cinnamate</p>	 <p>10024-56-3; Terpinyl cinnamate</p>	 <p>3901-07-3; Methyl (E)-p-methoxycinnamate</p>
 <p>103-61-7; Cinnamyl butyrate</p>	 <p>538-65-8; Butyl cinnamate</p>	 <p>238402-46-5; 2-Propenoic acid, 3-(2-hydroxyphenyl)-, 9-decen-1-yl ester, (2E)-</p>	 <p>7779-17-1; Cyclohexyl cinnamate</p>	 <p>7493-78-9; alpha-Amylcinnamyl acetate</p>	 <p>20883-16-3; 3-Phenyl-2-butenyl acetate</p>
 <p>103-59-3; Cinnamyl isobutyrate</p>	 <p>3487-99-8; Amyl cinnamate</p>	 <p>5466-77-3; 2-Propenoic acid, 3-(4-methoxyphenyl)-, 2-ethylhexyl ester</p>	 <p>7780-06-5; Isopropyl cinnamate</p>	 <p>5320-75-2; Cinnamyl benzoate</p>	 <p>87-29-6; Cinnamyl anthranilate</p>
 <p>140-27-2; Cinnamyl isovalerate</p>	 <p>10032-08-3; Heptyl cinnamate</p>	 <p>7492-65-1; Cinnamyl phenylacetate</p>	 <p>104-65-4; Cinnamyl formate</p>	 <p>103-26-4; Methyl cinnamate</p>	 <p>103-41-3; Benzyl cinnamate</p>
 <p>122-69-0; Cinnamyl cinnamate</p>	 <p>61792-12-9; Cinnamyl tiglate</p>	 <p>7493-79-0; alpha-Amylcinnamyl formate</p>	 <p>65505-25-1; Tetrahydrofurfuryl cinnamate</p>	 <p>78-37-5; Linalyl cinnamate</p>	







# The structurally related materials needed to be refined

 <p>104-65-4; Cinnamyl formate</p>	 <p>20883-16-3; 3-Phenyl-2-butenyl acetate</p>	 <p>61792-12-9; Cinnamyl tiglate</p>	 <p>122-67-8; Isobutyl cinnamate</p>	 <p>103-26-4; Methyl cinnamate</p>	 <p>122-69-0; Cinnamyl cinnamate</p>
 <p>103-54-8; Cinnamyl acetate</p>	 <p>7493-79-0; alpha-Amylcinnamyl formate</p>	 <p>7493-78-9; alpha-Amylcinnamyl acetate</p>	 <p>7779-65-9; Isoamyl cinnamate</p>	 <p>103-36-6; Ethyl cinnamate</p>	 <p>78-37-5; Linalyl cinnamate</p>
 <p>103-56-0; Cinnamyl propionate</p>	 <p>7493-80-3; alpha-Amylcinnamyl isovalerate</p>	 <p>5320-75-2; Cinnamyl benzoate</p>	 <p>7780-06-5; Isopropyl cinnamate</p>	 <p>7778-83-8; Propyl cinnamate</p>	 <p>65505-25-1; Tetrahydrofurfuryl cinnamate</p>
 <p>103-61-7; Cinnamyl butyrate</p>	 <p>68133-75-5; cis-3-Hexenyl cinnamate</p>	 <p>103-41-3; Benzyl cinnamate</p>	 <p>238402-46-5; 2-Propenoic acid, 3-(2-hydroxyphenyl)-, 9-decen-1-yl ester, (2E)-</p>	 <p>538-65-8; Butyl cinnamate</p>	 <p>3901-07-3; Methyl (E)-p-methoxycinnamate</p>
 <p>103-59-3; Cinnamyl isobutyrate</p>	 <p>7492-65-1; Cinnamyl phenylacetate</p>	 <p>103-53-7; Phenethyl cinnamate</p>	 <p>7779-17-1; Cyclohexyl cinnamate</p>	 <p>3487-99-8; Amyl cinnamate</p>	 <p>5466-77-3; 2-Propenoic acid, 3-(4-methoxyphenyl)-, 2-ethylhexyl ester</p>
 <p>140-27-2; Cinnamyl isovalerate</p>		 <p>122-68-9; 3-Phenylpropyl cinnamate</p>	 <p>10024-56-3; Terpinyl cinnamate</p>	 <p>10032-08-3; Heptyl cinnamate</p>	 <p>87-29-6; Cinnamyl anthranilate</p>





# This was the final cluster of materials to be considered based on chemical predictivity and expert judgement

 104-65-4; Cinnamyl formate	 103-26-4; Methyl cinnamate	 122-67-8; Isobutyl cinnamate	 122-69-0; Cinnamyl cinnamate
 103-54-8; Cinnamyl acetate	 103-36-6; Ethyl cinnamate	 7779-65-9; Isoamyl cinnamate	
 103-56-0; Cinnamyl propionate	 7778-83-8; Propyl cinnamate	 7780-06-5; Isopropyl cinnamate	 5320-75-2; Cinnamyl benzoate
 103-61-7; Cinnamyl butyrate	 538-65-8; Butyl cinnamate		 103-41-3; Benzyl cinnamate
 103-59-3; Cinnamyl isobutyrate	 3487-99-8; Amyl cinnamate		 103-53-7; Phenethyl cinnamate
 140-27-2; Cinnamyl isovalerate	 10032-08-3; Heptyl cinnamate	 122-68-9; 3-Phenylpropyl cinnamate	 122-68-9; 3-Phenylpropyl cinnamate

# The data on the structurally related materials confirmed this cluster can be used – no positive data

CAS	Name	Structure	Animal Data	Human Data	In-vitro	In-silico prediction	Clears reactive DST?
104-65-4	Cinnamyl formate			Neg hMAX @ 4%		Reactive	No
103-54-8	Cinnamyl acetate			Neg hMAX @ 5%	Neg DPRA, Neg h-CLAT	Reactive	No
103-56-0	Cinnamyl propionate			Neg hMAX @ 4%		Reactive	No
103-61-7	Cinnamyl butyrate			Neg hMAX @ 4%		Reactive	Yes

# A confirmatory HRIPT was conducted on cinnamyl acetate because it was the most reactive in the cluster

CAS	Name	Structure	Animal Data	Human Data	In-vitro	In-silico prediction	Clears reactive DST?	Safety Assessment
104-65-4	Cinnamyl formate			Neg hMAX @ 4%		Reactive	No	Safe under the current use level
103-54-8	Cinnamyl acetate			Neg HRIPT @ 2.9% (3424); Neg hMAX @ 5%	Neg DPRA, Neg h-CLAT	Reactive	No	Safe under the current use level
103-56-0	Cinnamyl propionate			Neg hMAX @ 4%		Reactive	No	Safe under the current use level
103-61-7	Cinnamyl butyrate			Neg hMAX @ 4%		Reactive	Yes	Safe under the current use level